Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5652369 | 0.98 | LSS (0.52) | LSSCHRNA7 | |
| SCHEMBL1018942 | 0.95 | LSS (0.57) | LSSCHRNA7 | |
| SCHEMBL31507154 | 0.95 | LSS (0.57) | LSSCHRNA7 | |
| SCHEMBL5420231 | 0.95 | LSS (0.57) | LSSCHRNA7 | |
| Hydrochloric Acid SCHEMBL5649595 | 0.94 | LSS (0.56) | LSSCHRNA7 | |
| SCHEMBL5390772 | 0.92 | LSS (0.60) | LSSCHRNA7 | |
| SCHEMBL5418233 | 0.91 | LSS (0.53) | LSSCHRNA7 | |
| SCHEMBL5706609 | 0.87 | LSS (0.53) | LSSCHRNA7 | |
| SCHEMBL5710323 | 0.87 | LSS (0.53) | LSSCHRNA7 | |
| SCHEMBL5710328 | 0.87 | LSS (0.53) | LSSCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241773-B2 | 3-quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | claimed |
| JP-2007515486-A | — | — | 2007-06-14 | — | — | JP | claimed |
| EP-1735305-A2 | 3-QUINUCLIDINYL HETEROATOM BRIDGED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2006-12-27 | — | — | EP | claimed |
| WO-2005066167-A2 | 3-QUINUCLIDINYL HETEROATOM BRIDGED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | claimed |
| US-7241773-B2 | 3-quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1735305-A2 | 3-QUINUCLIDINYL HETEROATOM BRIDGED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005066167-A2 | 3-QUINUCLIDINYL HETEROATOM BRIDGED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | CHRNA3, CHRNA1, CHRM3 | LSS 1730/4885CHRNA7 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.